Phoenix Bio

Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK__ model with enterohepatic circulation

Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK__ model with enterohepatic circulation

2025/09/17

Hirasawa, K. Adachi, T. Takeuchi, H. Kuroda, T. Abe, J. Nakajima, M.
Toxicol Appl Pharmacol. 2025 Aug 19;504:117525. doi: 10.1016/j.taap.2025.117525.

Modeling of hepatitis B virus infection spread in primary human hepatocytes

2025/09/17

Shi, Z. Tsuge, M. Collier, N. Takeuchi, Y. Uchida, T. Rutter, C. M. Teraoka, Y. Uprichard, S. L. Ishida, Y. Tateno, C. Ozik, J. Dahari, H. Chayama, K.
J Virol. 2025 Aug 4:e0092725. doi: 10.1128/jvi.00927-25.

Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model

2025/09/17

Visser, B. J. Biswas, S. Eltahan, R. Fares-Gusmao, R. Yegneswaran, S. Mufti, N. Villa, C. H. McGivern, D. R.
Transfusion. 2025 Jul 24. doi: 10.1111/trf.18357.

miRNA-29b-1-5p mediates an antiviral activity by targeting the HBV entry receptor in human hepatocytes

2025/09/17

Gailhouste, L. Furutani, Y. Qin, X. Y. Higuchi, S. Toguchi, M. Yanaka, K. Watashi, K. Wakita, T. Kojima, S.
Sci Rep. 2025 Jul 3;15(1):23725. doi: 10.1038/s41598-025-09655-y.

Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

2025/09/17

Zhou, J. Kaiser, H. Rocha, E. Terrell, A. N. Corti, D. Purcell, L. A. Lempp, F. A. Puschnik, A. S.
JHEP Rep. 2025 Mar 22;7(6):101400. doi: 10.1016/j.jhepr.2025.101400. eCollection

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

2025/09/17

Kawamoto, K.Shimotsuma, Y.Maeda, K. Matsunaga, K. Asano, H. Cohen, S. M. Yamada, T.
Arch Toxicol. 2025 Jun 9. doi: 10.1007/s00204-025-04099-9.

Quantitative Prediction of Drug-Drug Interactions Arising from CYP3A4 Induction using Chimeric Mice with Humanized Liver

2025/09/17

Nakayama, K. Negoro, T. Takubo, H. Hayashi, A. Taniguchi, T. Nomura, Y. Iwanaga, K.
Xenobiotica. 2025 Jun 11:1-19. doi: 10.1080/00498254.2025.2518239.

Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action

2025/09/17

Tanaka, Yasuhito
Glob Health Med. 2025 Feb 28;7(1):64-66. doi: 10.35772/ghm.2024.01078.

Application of humanized mice to toxicology studies: properties of chimeric mice with humanized liver (PXB-mice) for hepatotoxicity

Sultana, N. Izawa, T. Kamei, T. Fujiwara, S. Ito, Y. Takami, Y. Kuwamura, M.
Drug Metab Dispos. 2025 Feb;53(2):100025. doi: 10.1016/j.dmd.2024.100025.

第52回日本毒性学会学術年会でのランチョンセミナー開催及び企業展示のご案内

2025/06/05

2025年7月2日(水)~4日(金)に沖縄コンベンションセンターで開催されます第52回日本毒性学会学術年会にて、
ランチョンセミナーを開催致します。
企業展示も行いますので、ご来場の方はぜひお立ち寄りください。

Identification of glycogen synthase kinase 3alpha/beta as a host factor required for HBV transcription using high-throughput screening

2025/05/08

Nishitsuji, H. Naito, Y. Murakami, Y. Sugiyama, M. Mizokami, M. Shoji, I. Murata, T. Shimotohno, K.
Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001239.

Identification of novel antiviral host factors by functional gene expression analysis using in vitro HBV infection assay systems

2025/05/08

Nosaka, T. Naito, T. Akazawa, Y. Takahashi, K. Matsuda, H. Ohtani, M. Nishizawa, T. Okamoto, H. Nakamoto, Y.
PLoS One. 2025 Mar 6;20(3):e0314581. doi: 10.1371/journal.pone.0314581.

Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice

2025/05/08

Miyake, T. Fujita, Y. Hirabayashi, M. Komiyama, N. Morita, K. Tachibana, T. Terao, K.
Drug Metab Dispos. 2025 Feb 10;53(4):100050. doi: 10.1016/j.dmd.2025.100050.

Development of human growth hormone-treated chimeric mice with humanized livers for an evaluation model of drug-induced fatty liver disease

2025/05/08

Morioka, S. Sanoh, S. Ishida, Y. Furukawa, S. Ogawa, Y.Kotake, Y. Tateno, C.
Arch Toxicol. 2025 Feb 21. doi: 10.1007/s00204-025-03986-5.

Investigation of Biotransformation Pathways in a Chimeric Mouse with a Humanized Liver

2025/05/08

Karlsson, I. B. Ekdahl, A. Etchingham-Coll, H. Li, X. Q. Ericsson, C. Ahlqvist, M. Samuelsson, K.
Int J Mol Sci. 2025 Jan 28;26(3):1141. doi: 10.3390/ijms26031141

Endothelial lipase-binding peptides similar to netrin-1 inhibit hepatitis B virus infection

2025/05/08

Ide, M. Tabata, N. Murai, K. Yonemura, Y. Wang, Y. Ishida, A. Shirasaki, T. Kaneko, S. Ito, S. Honda, M. Yanagawa, H.
FEBS Lett. 2025 Jan 25. doi: 10.1002/1873-3468.15101.

Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation

2025/05/08

Ito, M. Liu, J. Fukasawa, M. Tsutsumi, K. Kanegae, Y. Setou, M. Kohara, M. Suzuki, T.
JHEP Rep. 2024 Sep 30;7(1):101225. doi: 10.1016/j.jhepr.2024.101225.

Hepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene

2025/05/08

Zhang, M. Mouzannar, K. Zhang, Z. Teraoka, Y. Piotrowski, J. Ishida, Y. Tateno-Mukaidani, C. Saito, T.Abe-Chayama, H. Chayama, K.Liang, T. J.
PLoS Pathog. 2025 Jan 9;21(1):e1012803. doi: 10.1371/journal.ppat.1012803.

Theoretical modeling of hepatitis C acute infection in liver-humanized mice support pre-clinical assessment of candidate viruses for controlled-human-infection studies

2025/05/08

Shi, Z. Mhlanga, A. Ishida, Y. Josephson, A. Collier, N. T. Abe-Chayama, H. Tateno-Mukaidani, C. Cotler, S. J. Ozik, J. Major, M. Feld, J. J. Chayama, K. Dahari, H.
Sci Rep. 2024 Dec 30;14(1):31826. doi: 10.1038/s41598-024-83104-0.

Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver

2025/05/08

Bao, H. Murakami, S. Tsuge, M. Uchida, T. Uchikawa, S. Fujino, H. Ono, A. Murakami, E. Kawaoka, T. Miki, D. Hayes, C. N. Oka, S.
Viruses. 2024 Nov 6;16(11):1743. doi: 10.3390/v16111743.